{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:56:59Z","timestamp":1773323819757,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,10,4]],"date-time":"2007-10-04T00:00:00Z","timestamp":1191456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Compr Ther"],"published-print":{"date-parts":[[2007,11,1]]},"DOI":"10.1007\/s12019-007-8003-x","type":"journal-article","created":{"date-parts":[[2007,10,3]],"date-time":"2007-10-03T13:53:51Z","timestamp":1191419631000},"page":"78-81","source":"Crossref","is-referenced-by-count":18,"title":["Submicrobial Doxycycline and Rosacea"],"prefix":"10.1007","volume":"33","author":[{"given":"Ronald D.","family":"Wise","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,4]]},"reference":[{"key":"8003_CR1","unstructured":"Sande MA, Mandell GL. Antimicrobial agents. In: Gilman, AG, Rall, TW, Nies, AS, Taylor, P, editors. Goodman and Gilman\u2019s the pharmacological basis of therapeutics. 8th ed. McGraw-Hill; 1993. p.1117\u201325."},{"key":"8003_CR2","first-page":"357","volume-title":"Principles and practice of infectious diseases","author":"B Meyers","year":"2005","unstructured":"Meyers B, Salvatore M. Tetracyclines and chloramphenicol. In: Mandell Gl, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia, PA: Elsevier; 2005. p. 357\u201366."},{"issue":"4","key":"8003_CR3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/CMR.5.4.387","volume":"5","author":"BS Speer","year":"1992","unstructured":"Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: Mechanisms, transfer, and clinical significance. Clin Microbiol Rev 1992;5(4):38\u201399.","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"8003_CR4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1540-9740.2003.03014.x","volume":"2","author":"JB Bikowski","year":"2003","unstructured":"Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. SKINmed 2003;2(4):234\u201345, Review.","journal-title":"SKINmed"},{"issue":"1","key":"8003_CR5","first-page":"16","volume":"5","author":"HE Baldwin","year":"2006","unstructured":"Baldwin HE. Oral therapy for rosacea. J Drugs Dermatol 2006;5(1):16\u201321.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"8003_CR6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/scientificamerican0398-46","volume":"278","author":"SB Levy","year":"1998","unstructured":"Levy SB. The challenge of antibiotic resistance. Sci Am 1998;278(3):46\u201353.","journal-title":"Sci Am"},{"key":"8003_CR7","first-page":"95","volume":"1115","author":"JM Bernstein","year":"1999","unstructured":"Bernstein JM. Treatment of community-acquired pneumonia-IDSA guidelines. Chest 1999;1115:95\u2013135.","journal-title":"Chest"},{"key":"8003_CR8","unstructured":"Stanford Hospital & Clinics. Antibiotic susceptibility of bacteria and yeasts. Available at: http:\/\/med.stanford.edu\/lane\/schid\/susceptibility\/ReportB.htm . (Accessed February 10, 2006)."},{"key":"8003_CR9","unstructured":"US Food and Drug Administration. FDA publishes final rule to require labeling about antibiotic resistance. FDA News. Available at: http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2003\/NEW00869.html . (Accessed February 10, 2006)."},{"issue":"8","key":"8003_CR10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMcp042829","volume":"352","author":"FC Powell","year":"2005","unstructured":"Powell FC. Rosacea. N Engl J Med 2005;352(8):793\u2013803.","journal-title":"N Engl J Med"},{"key":"8003_CR11","unstructured":"National Rosacea Society. 14 million Americans urged to face up to rosacea before it gets worse. News Releases. April; 1, 2005. Available at: http:\/\/www.rosacea.org\/press\/archive\/20050401.html . (Accessed February 10, 2006)."},{"issue":"1","key":"8003_CR12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1540-9740.2003.01876.x","volume":"2","author":"L Milliklin","year":"2003","unstructured":"Milliklin L. The proposed inflammatory pathophysiology of rosacea: Implications for treatment. SKINmed 2003;2(1):43\u20137.","journal-title":"SKINmed"},{"issue":"5","key":"8003_CR13","first-page":"419","volume":"69","author":"M Berg","year":"1989","unstructured":"Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venerol 1989;69(5):419\u201323.","journal-title":"Acta Derm Venerol"},{"issue":"6","key":"8003_CR14","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaad.2004.01.048","volume":"50","author":"J Wilkin","year":"2004","unstructured":"Wilkin J, Dahl M, Detmar M. et al. Standard classification of rosacea. Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2004;50(6):907\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"8003_CR15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2004.03.030","volume":"51","author":"GH Crawford","year":"2004","unstructured":"Crawford GH, Pelle MT, James, WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004;51(3):327\u201341.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"8003_CR16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"J Wilkin","year":"2002","unstructured":"Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea. Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002;46(4):584\u201387.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"8003_CR17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/014107689709000308","volume":"90","author":"T Jansen","year":"1997","unstructured":"Jansen T, Plewig GJ. Rosacea: classification and treatment. R Soc Med 1997;90(3):144\u201350.","journal-title":"R Soc Med"},{"issue":"2","key":"8003_CR18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000082564","volume":"201","author":"SA Buechner","year":"2005","unstructured":"Buechner SA. Rosacea: An update. Dermatology 2005;201(2):100\u20138.","journal-title":"Dermatology"},{"issue":"6","key":"8003_CR19","first-page":"38","volume":"2","author":"JB Bikowski","year":"2005","unstructured":"Bikowski JB. What you should know about subantimicrobial dose doxycycline. Pract Dermatol 2005;2(6):38\u201343.","journal-title":"Pract Dermatol"},{"issue":"Suppl 3","key":"8003_CR20","first-page":"17","volume":"74","author":"D Jones","year":"2004","unstructured":"Jones D. Reactive oxygen species and rosacea. Cutis 2004;74(Suppl 3):17\u201320, Review.","journal-title":"Cutis"},{"issue":"6","key":"8003_CR21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02850193","volume":"18","author":"Y Miyachi","year":"2001","unstructured":"Miyachi Y. Potential antioxidant mechanism of action for metronidazole: Implications for rosacea management. Adv Ther 2001;18(6):237\u201343.","journal-title":"Adv Ther"},{"issue":"12","key":"8003_CR22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.1966.tb12168.x","volume":"78","author":"IB Sneddon","year":"1966","unstructured":"Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966;78(12):649\u201352.","journal-title":"Br J Dermatol"},{"issue":"2","key":"8003_CR23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","volume":"54","author":"AN Sapadin","year":"2006","unstructured":"Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54(2):258\u201365.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"8003_CR24","first-page":"118","volume":"74","author":"JQ Russo Del","year":"2004","unstructured":"Del Russo JQ. The antibiotic paradox: benefits and risks of using antimicrobial oral antibiotics for the systemic treatment of rosacea. Cutis 2004;74(2):118\u201322.","journal-title":"Cutis"},{"issue":"2","key":"8003_CR25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/08959374980120010501","volume":"12","author":"LM Golub","year":"1998","unstructured":"Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12(2):12\u201326.","journal-title":"Adv Dent Res"},{"issue":"special issue","key":"8003_CR26","first-page":"245","volume":"69","author":"K Schroeder","year":"1990","unstructured":"Schroeder K, Lee H, Wolff M, et al. Low-dose tetracyclines (TCs) decrease elastase and beta-glucuronidase activities in gingival crevicular fluid (GCF) [abstract 1090]. J Dent Res 1990;69(special issue):245.","journal-title":"J Dent Res"},{"key":"8003_CR27","first-page":"758","volume":"71","author":"KL Schroeder","year":"1992","unstructured":"Schroeder KL, Ramamurphy NS, Szczepanek KA, et al. Low\u2013dose tetracycline prevents attachment loss in adult periodontitis [abstract 1936]. J Dent Res 1992;71:758.","journal-title":"J Dent Res"},{"issue":"4","key":"8003_CR28","first-page":"459","volume":"39","author":"R Skidmore","year":"2003","unstructured":"Skidmore R, Kovach R, Walker C, et al. Effects of submicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003;39(4):459\u201364.","journal-title":"Arch Dermatol"},{"key":"8003_CR29","first-page":"36","volume":"11","author":"JQ Rosso Del","year":"2004","unstructured":"Del Rosso JQ, Bikowski J. When is an antibiotic not an antibiotic? Skin & Aging. 2004;11:36\u201342.","journal-title":"Skin & Aging"},{"key":"8003_CR30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.14219\/jada.archive.1994.0261","volume":"125","author":"LM Golub","year":"1994","unstructured":"Golub LM, Wolff M, Roberts S, et al. Treating periodontal diseases by blocking tissue-destructive enzymes. J Am Dent Assoc 1994;125:163\u201369 (discussion 169\u201371).","journal-title":"J Am Dent Assoc"},{"key":"8003_CR31","unstructured":"Oracea. Newtown, PA: CollaGenex Pharmaceuticals; 2006 (prescribing information)."}],"container-title":["Comprehensive Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12019-007-8003-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12019-007-8003-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12019-007-8003-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:48:30Z","timestamp":1559440110000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12019-007-8003-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,11,1]]}},"alternative-id":["8003"],"URL":"https:\/\/doi.org\/10.1007\/s12019-007-8003-x","relation":{},"ISSN":["0098-8243","1559-1190"],"issn-type":[{"value":"0098-8243","type":"print"},{"value":"1559-1190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,4]]}}}